The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Outcome Measures, 2021Development and Validation of a Sensitive Method for Measuring PINK
Study Rationale: Mutations in PINK1 are linked to familial Parkinson’s disease (PD), but their role in sporadic forms of the disorder are not clear. The PINK1 protein works with PRKN to dispose of...
-
Fall 2021 RFP: Expanding Biological Understanding of PD, 2021Studying How Defects in Autophagy Contribute to the Aggregation of Alpha-synuclein in Neurons with LRRK2 Mutations
Study Rationale: Mutations in the LRRK2 gene are the most frequent cause of inherited forms of Parkinson’s disease (PD). We have found that these mutations disrupt autophagy—a process that cells...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Development of an Inhibitor of Tau Aggregation to Treat Parkinson’s Disease
Study Rationale: The formation of tau aggregates is caused by excessive modification and abnormal folding of the tau protein in the brain, which leads to cellular dysfunction and neurodegeneration...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Preclinical Studies of Compounds that Block Alpha-synuclein Aggregation by Antagonizing the Sigma-2 Receptor
Study Rationale: There is a dire need to discover and develop novel therapeutics for Parkinson’s disease (PD), a disorder for which no disease-modifying therapies exist. Targeting the sigma-2 receptor...
-
Research Grant, 2021Evaluation of Digital Mobility Data to Identify Individuals at Risk of Developing Parkinson’s Disease
Study Rationale: Gait disturbances play a major role in the motor manifestation of Parkinson’s disease (PD). Traditional clinical assessments aimed at measuring motor deficits do not sufficiently...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Investigating the Neuroprotective Potential and Mechanism of Action of an Inhibitor of the Rho-associated Protein Kinase (ROCK)
Study Rationale: Altered signaling through the Rho-associated protein kinase (ROCK) pathway has been found to play a role in the cellular pathogenesis of Parkinson’s disease (PD). Previously, we...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.